There's no phase 2 completion data on the GBM trials, or any of...

There's no phase 2 completion data on the GBM trials, or any of the others. Would have been nice if the preliminary data made a move in the share price, but it's irrelevant until the data from any of the trials is completed anyway. Pointing at dates along the google kza chart means nothing. You can do that with a lot of random shares at the Monet with the nature of covid-19.

The safer the drug looks and the more efficacious it looks with each preliminary data set release, the safer the bet is on the drug and the company. Why so many people moan about the cheap price with the knowledge of its safety and efficacy is beyond me.

Always make your own cheesecake imo